 | | Vol. 11.37 – 2 October, 2020 |
| |
|
|
| Researchers demonstrated that protein arginine methyltransferase 5 functions as an epigenetic activator of androgen receptor transcription in castration-resistant prostate cancer, requiring cooperation with a methylosome subunit pICln.
[Cancer Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated the anticancer effects of botanical component p-hydroxycinnamic acid on the PC-3 cells in vitro model of bone metastatic human prostate cancer.
[Cancer Research] |
|
|
|
| The role of truncated AR-V7 in prostate cancer biology is an unresolved question.The correlation between resistance to AR signaling inhibitors and genetic chances and expression of full length AR vs. AR-V7 were evaluated in a series of independent patient-derived xenografts.
[Oncogene] |
|
|
|
| Investigators studied whether testosterone and androgen receptor signaling interfered with docetaxel treatment efficacy in castration-resistant prostate cancer.
[British Journal of Cancer] |
|
|
|
| The authors present a new protocol based on surface enhanced resonance Raman scattering (SERRS) gold multivalent nanostructures to identify and enumerate tumor cells with epithelial and mesenchymal markers.
[Scientific Reports] |
|
|
|
| Researchers identified a compound which displayed powerful anticancer activity with the IC50 value of 0.81µM against PC3 cells, which was significantly better than 5-fluorouracil. It could inhibit tubulin polymerisation binding at the colchicine site and inhibit the tumour growth in vitro and in vivo.
[Journal of Enzyme inhibition and Medicinal Chemistry] |
|
|
|
| In vitro, N‑Myc proto‑oncogene protein and fascin (FSCN1) were overexpressed in LNCaP and C4‑2 cell lines. The results revealed the promoting effect of N‑Myc and FSCN1 on malignant progression of prostate cancer.
[Oncology Reports] |
|
|
|
|
| Considering direct mechanisms, chelators can bind zinc(II) that plays a catalytic role in enzyme activity. In terms of indirect mechanisms, Dp44mT and DpC potently suppress the expression of the kallikrein-related peptidase—a prostate-specific antigen—in prostate cancer cells.
[International Journal of Molecular Sciences] |
|
|
|
|
| Veru, Inc. has announced that it has fully enrolled its Phase II clinical study of VERU-111, its novel, oral, alpha and beta tubulin targeting drug for metastatic castration and novel androgen receptor targeting agent resistant prostate cancer. The study enrolled a total of 40 men at 13 clinical sites in the US.
[Veru Inc.] |
|
|
|
| LIDDS AB announced results from the voluntary open-label extension of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50% of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection.
[LIDDS AB (GlobeNewswire, Inc.)] |
|
|
|
|
| October 13 – October 14
Virtual |
|
|
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Princess Margaret Cancer Center – Toronto, Ontario, Canada |
|
|
|
| | University of Miami – Miami, Flordia, United States |
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | Brigham and Women’s Hospital, Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
